Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells

Toxicology in Vitro

Volumn 29, Issue 3, 2015, Pages 512-521

  Wojcik, Tomasz ^a   Buczek, Elzbieta ^a   Majzner, Katarzyna ^a   Kolodziejczyk, Agnieszka ^a   Miszczyk, Justyna ^b   Kaczara, Patrycja ^a   Kwiatek, Wojciech ^b   Baranska, Malgorzata ^a   Szymonski, Marek ^a   Chlopicki, Stefan ^a,c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF NUCLEAR PHYSICS   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cytotoxicity; Daunorubicin; Doxorubicin; Endothelium; High content screening

Indexed keywords

CASPASE 3; CASPASE 7; DAUNORUBICIN; DNA; DOXORUBICIN; F ACTIN; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; ACTIN; ANTINEOPLASTIC ANTIBIOTIC; CASPASE;

ANIMAL CELL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CELL CULTURE; CELL MEMBRANE; CELL NUCLEUS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINESIS; CYTOSKELETON; CYTOSOL; DNA DAMAGE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG POTENCY; ELASTICITY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAMAN SPECTROMETRY; VASCULAR RING; ANIMAL; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; METABOLISM; THORACIC AORTA;

ACTINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AORTA, THORACIC; CASPASES; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DAUNORUBICIN; DOXORUBICIN; ENDOTHELIAL CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; IN VITRO TECHNIQUES; MICE; REACTIVE OXYGEN SPECIES;

EID: 84921534733     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.12.009     Document Type: Article

References (37)

1. Bains O.S., Szeitz A., Lubieniecka J.M., Cragg G.E., Grigliatti T.A., Riggs W.K., Reid R.E. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J. Pharmacol. Exp. Ther. 2013, 347:375-387.
2. Chow A.Y., Chin C., Dahl G., Rosenthal D.N. Anthracyclines caused endothelial injury in pediatric cancer patients: a pilot study. J. Clin. Oncol. 2006, 24:925-928.
3. Cortez D., Guntuku S., Qin J., Elledge S.J. ATR and ATRIP: partners in checkpoint signaling. Science 2001, 294:1713-1716.
4. Damrot J., Nubel T., Epe B., Roos W.P., Kaina B., Fritz G. Lovastatin protects human endothelial cells from genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 2006, 149:988-997.
5. Dengel D.R., Ness K.K., Glasser S.P., Williamson E.B., Baker K.S., Gurney J.G. Endothelial function in young adult survivors of childhood acute lymphoblastic leukaemia. J. Pediatr. Hematol. Oncol. 2008, 30:20-25.
6. Diers A.R., Broniowska K.A., Hogg N. Nitrosative stress and redox-cycling agents synergize to cause mitochondrial dysfunction and cell death in endothelial cells. Redox. Biol. 2013, 1:1-7.
7. Duquaine D., Hirsch G.A., Chakrabarti A., Han Z., Kehrer C., Brook R., et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for adysfunctional nitric oxide synthase. Vasc. Med. 2003, 8:101-107.
8. Edgell C.J., Mcdonald C.C., Graham J.B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Cell. Biol. 1983, 80:3734-3737.
9. Faneyette I.F., Kristel P.M.P., Van De Vijver M.J. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res. 2004, 24:2931-2940.
10. Feng R., Zhai W.Z., Yang H.Y., Jin H., Zhang Q.X. Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK. Biochem. Biophys. Res. Commun. 2011, 406:299-304.
11. Friedberg E.C., Wallner G.C., Siede W. DNA Repair and Mutagenesis 1995, ASM Press, Washington.
12. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
13. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox. Biol. 2013, 1:244-257.
14. Kaushal V., Kaushal G.P., Mehta P. Differential toxicity of anthracyclines on cultured endothelial cells. Endothelium 2004, 11(5-6):253-258.
15. Kirsch-Volders M., Sofuni T., Aardema M., Albertini S., Eastmond D., Fenech M., Ishidate M., Lorge E., Norppa H., Surrallés J., von der Hude W., Wakata A. Report from the in vitro micronucleus assay working group. Environ. Mol. Mutagen 2000, 35(3):167-172.
16. Kokenberg E., Sonneveld P., Sizoo W., Hagenbeek A., Lowenberg B. Cellular pharmacokinetics of daunorubicin: relationship with response to treatment in patients with acute myeloid leukaemia. J. Clin. Oncol. 1988, 6:802-812.
17. Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: Intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 2004, 279(24):25535-25543.
18. Lee V., Randhawa P.K., Singal P.K. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am. J. Physiol. 1991, 261(4):H989-H995.
19. Meriwether W.D., Bachur N.R. Inhibition of DNA and RNA metabolism by Daunorubicin and Adriamycin in L1210 Mouse Leukaemia. Cancer Res. 1972, 32:1137-1142.
20. Muller C., Chatelut E., Gualano V., De Forni M., Huguet F., Attal M., Canal P., Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukaemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol. 1993, 32:379-384.
21. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 2012, 52:1213-1225.
22. Sahin E., Colla S., Liesa M., Moslehi J., Müller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., Maser R.S., Tonon G., Foerster F., Xiong R., Wang Y.A., Shukla S., Jaskelioff M., Martin E.S., Heffernan T.P., Protopopov A., Ivanova E., Mahoney J.E., Kost-Alimova M., Perry S.R., Bronson R., Liao R., Mulligan R., Shirihai O.S., Chin L., DePinho R. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470(7334):359-365.
23. Schäffer T.E. Calculation of thermal noise in an atomic force microscope with a finite optical spot size. Nanotechnology 2005, 16(6):664-670.
24. Shapiro C.I., Hardenbergh P.H., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. 1998, 16:3493-3501.
25. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 2001, 11:71-77.
26. Singal P.K., LIiskovic N. Doxorubicin-induced cardiomyopathy. N. Eng. J. Med. 1998, 339:900-905.
27. Sneddon I.N. The relation between load and penetration in the axisymmetric Boussinesq problem for a punch of arbitrary profile. Int. J. Eng. Sci. 1965, 3:47-57.
28. Soultati A., Mountzios G., Avgerinou C., Papxoinis G., Pectasides D., Dimopoulos M.-A., Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012, 38:473-483.
29. Steinherz P.G., Redner A., Steinherz L., et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 1993, 72:3120-3130.
30. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
31. Szczygiel A.M., Brzezinka G., Targosz-Korecka M., Chlopicki S., Szymonski M. Elasticity changes anti-correlate with NO production for human endothelial cells stimulated with TNF-α. Pflugers Arch. 2012, 463(3):487-493.
32. Tzima E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ. Res. 2006, 98:176-185.
33. Vavrova A., Jansova H., Mackova E., Machacek M., Haskova P., Tichotova L., Sterba M., Simunek T. Catalytic inhibitors of Topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLOS One 2013, 8:e76676.
34. Wojcik K., Zarebski M., Cossarizza A., Dobrucki J.W. Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions. Cancer Biol. Ther. 2013, 14(9):1-10.
35. Wolf M.B., Baynes J.W. The anti-cancer drug, doxorubicin, cause oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta 2006, 1760:267-271.
36. Zhang J.H. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 1999, 4(2):67-73.
37. Zhang S., Liu X., Bawa-Khalfe T., Lu L.-S., Lyu Y.L., Liu L.F., Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012, 18(11):1639-1642.